Open-label dose confirmation and dosimetry study of interstitial 131I-chTNT-1/B mAb (Cotara) for the treatment of recurrent glioblastoma multiforme.

Trial Profile

Open-label dose confirmation and dosimetry study of interstitial 131I-chTNT-1/B mAb (Cotara) for the treatment of recurrent glioblastoma multiforme.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Nov 2016

At a glance

  • Drugs Iodine I 131 derlotuximab biotin (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Sponsors Peregrine Pharmaceuticals
  • Most Recent Events

    • 14 Mar 2011 Results will be presented by mid-2011.
    • 31 Dec 2010 Status changed from active, no longer recruiting to completed.
    • 13 Apr 2010 Results will be presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held June 4-8, 2010 in Chicago, Illinois.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top